Avadel Pharmaceuticals to Present at Upcoming Investor Conferences
March 05, 2025 08:00 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, March 05, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that...
Avadel Pharmaceuticals Reiterates 2025 Guidance as it Reports Fourth Quarter and Full Year 2024 Financial Results
March 03, 2025 07:00 ET
|
Avadel Pharmaceuticals plc
-- LUMRYZ™ generated $50.4 million in sales in the fourth quarter, up 158% year-over-year, taking the full-year total to $169.1 million, in line with preliminary results published January 8 --...
Avadel Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on March 3
February 24, 2025 16:05 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will...
Avadel Pharmaceuticals Appoints Kevin Springman as Vice President of Sales
February 24, 2025 08:00 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced that Kevin Springman...
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
February 20, 2025 16:05 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee...
Avadel Pharmaceuticals Appoints Sev Melkonian as Vice President of Patient Services, Distribution, and Reimbursement
January 22, 2025 08:00 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Ireland, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that...
Avadel Announces Preliminary 2024 Results and 2025 Commercial Priorities to Accelerate the LUMRYZ Launch
January 08, 2025 16:15 ET
|
Avadel Pharmaceuticals plc
-- Approximately $50.0 million of net revenue from sales of LUMRYZ™ estimated for the fourth quarter, a greater than 150% increase over $19.5 million for the comparable period in 2023 -- --2,500...
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
January 06, 2025 16:05 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee...
Avadel Pharmaceuticals to Provide a Corporate Update and Preliminary Fourth Quarter and Full Year 2024 Financial Highlights on January 8
January 03, 2025 08:00 ET
|
Avadel Pharmaceuticals plc
DUBLIN, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will...
Results from Social Listening Analysis and Survey of People with Narcolepsy Uncover Real-Life Challenges with Twice-Nightly Oxybate Therapy
December 11, 2024 08:00 ET
|
Avadel Pharmaceuticals plc
– Findings published in Brain Sciences showed missed doses and potential for injury when waking to take a second dose among the key challenges – DUBLIN, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Avadel...